Document is current
Any future updates will be listed below
-
Authors
Vogelberg, Christian
Cuevas Schacht, Francisco
Watling, Christopher P.
Upstone, Laura
Seifert, Georg
-
Funding
Funding for this research was provided by:
Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden
- License Information
-
More Information
Article History
Received: 15 July 2022
Accepted: 20 December 2022
First Online: 21 January 2023
Declarations
:
: The survey was conducted in accordance with the Market Research Society (MRS) Code of Conduct. Formal ethics approval is not required for market research as outlined in the Health Research Authority (London, UK) ‘Governance Arrangements for Research Ethics Committees’ document. The survey participants gave digital written informed consent prior to starting the questionnaire (no minors took part in the survey). Questionnaire responses were anonymous, and no information was requested that would allow individuals to be identified.
: Not applicable.
: CV has received study, lecture or consulting fees from AstraZeneca, Boehringer Ingelheim, Engelhard Arzneimittel GmbH & Co. KG, Novartis Pharma, and Sanofi Aventis. FCS has been a speaker for AstraZeneca, Boehringer Ingelheim, Carnot Laboratorios, Glaxo, MSD, Novartis Pharma, and Sanofi Aventis. CPW and LU are employees of Cambridge – a Prime Global Agency, which received funding from Engelhard Arzneimittel GmbH & Co. KG for this work. GS has received honoraria from Dr. Willmar Schwabe GmbH & Co. KG for scientific services.
